Insider Selling: Leonard Oppenheim Unloads 15,212 Shares of Apricus Biosciences Stock (APRI)
Apricus Biosciences (NASDAQ:APRI) Director Leonard Oppenheim unloaded 15,212 shares of the company’s stock on the open market in a transaction dated Friday, January 3rd. The shares were sold at an average price of $2.49, for a total value of $37,877.88. Following the sale, the director now directly owns 20,449 shares of the company’s stock, valued at approximately $50,918. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Apricus Biosciences (NASDAQ:APRI) traded up 0.40% during mid-day trading on Monday, hitting $2.50. 296,298 shares of the company’s stock traded hands. Apricus Biosciences has a 52 week low of $1.66 and a 52 week high of $3.49. The stock’s 50-day moving average is $2.04 and its 200-day moving average is $2.11. The company’s market cap is $93.8 million.
Apricus Biosciences, Inc, formerly NexMed, Inc, is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.